Diabetic Retinopathy (Metabolic Disorder) - Drugs in Development, 2021

Diabetic Retinopathy (Metabolic Disorder) - Drugs in Development, 2021

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Retinopathy - Drugs In Development, 2021, provides an overview of the Diabetic Retinopathy (Metabolic Disorders) pipeline landscape.Diabetic retinopathy is a complication of diabetes that affects the eyes. Diabetic retinopathy symptoms may include spots or dark strings floating in vision (floaters), blurred vision, fluctuating vision, vision loss and difficulty with color perception. The predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy and tobacco use.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Diabetic Retinopathy - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Diabetic Retinopathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Diabetic Retinopathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Retinopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 6, 16, 13, 2, 78, 22 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 8 and 2 molecules, respectively.

Diabetic Retinopathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Retinopathy (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Diabetic Retinopathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Retinopathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Retinopathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Retinopathy (Metabolic Disorders)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Retinopathy (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Retinopathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Introduction
Diabetic Retinopathy - Overview
Diabetic Retinopathy - Therapeutics Development
Diabetic Retinopathy - Therapeutics Assessment
Diabetic Retinopathy - Companies Involved in Therapeutics Development
Diabetic Retinopathy - Drug Profiles
Diabetic Retinopathy - Dormant Projects
Diabetic Retinopathy - Discontinued Products
Diabetic Retinopathy - Product Development Milestones
Appendix

List Of Tables


Number of Products under Development for Diabetic Retinopathy, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Diabetic Retinopathy - Pipeline by 4D Molecular Therapeutics Inc, 2021
Diabetic Retinopathy - Pipeline by A6 Pharmaceuticals LLC, 2021
Diabetic Retinopathy - Pipeline by Accuitis Pharmaceuticals Inc, 2021
Diabetic Retinopathy - Pipeline by Adverum Biotechnologies Inc, 2021
Diabetic Retinopathy - Pipeline by Aerie Pharmaceuticals Inc, 2021
Diabetic Retinopathy - Pipeline by Afecta Pharmaceuticals Inc, 2021
Diabetic Retinopathy - Pipeline by Alkahest Inc, 2021
Diabetic Retinopathy - Pipeline by Angios GmbH, 2021
Diabetic Retinopathy - Pipeline by Antisense Therapeutics Ltd, 2021
Diabetic Retinopathy - Pipeline by AntlerA Therapeutics Inc, 2021
Diabetic Retinopathy - Pipeline by Apexian Pharmaceuticals Inc, 2021
Diabetic Retinopathy - Pipeline by Applied Therapeutics Inc, 2021
Diabetic Retinopathy - Pipeline by AptaBio Therapeutics Inc, 2021
Diabetic Retinopathy - Pipeline by Aptamer Sciences Inc, 2021
Diabetic Retinopathy - Pipeline by Araim Pharmaceuticals Inc, 2021
Diabetic Retinopathy - Pipeline by Ascentage Pharma Group International, 2021
Diabetic Retinopathy - Pipeline by Aviceda Therapeutics, 2021
Diabetic Retinopathy - Pipeline by Avirmax Inc, 2021
Diabetic Retinopathy - Pipeline by Bayer AG, 2021
Diabetic Retinopathy - Pipeline by BetaStem Therapeutics Inc, 2021
Diabetic Retinopathy - Pipeline by Bio-Thera Solutions Ltd, 2021
Diabetic Retinopathy - Pipeline by Boehringer Ingelheim International GmbH, 2021
Diabetic Retinopathy - Pipeline by Bonac Corp, 2021
Diabetic Retinopathy - Pipeline by CCRP Therapeutics GmbH, 2021
Diabetic Retinopathy - Pipeline by Cell Care Therapeutics Inc, 2021
Diabetic Retinopathy - Pipeline by Celros Biotech Co Ltd, 2021
Diabetic Retinopathy - Pipeline by Luye Pharma Group Ltd, 2021
Diabetic Retinopathy - Pipeline by Mabion SA, 2021
Diabetic Retinopathy - Pipeline by MingSight Pharmaceuticals Inc, 2021
Diabetic Retinopathy - Pipeline by Mirae Cell Bio Co Ltd, 2021
Diabetic Retinopathy - Pipeline by NB Health Laboratory Co Ltd, 2021
Diabetic Retinopathy - Pipeline by NeuMedics Inc, 2021
Diabetic Retinopathy - Pipeline by Neurodegeneration Therapeutics Inc, 2021
Diabetic Retinopathy - Pipeline by NGM Biopharmaceuticals Inc, 2021
Diabetic Retinopathy - Pipeline by Novago Therapeutics AG, 2021
Diabetic Retinopathy - Pipeline by Novelty Nobility Inc, 2021
Diabetic Retinopathy - Pipeline by Noveome Biotherapeutics Inc, 2021
Diabetic Retinopathy - Pipeline by OccuRx Pty Ltd, 2021
Diabetic Retinopathy - Pipeline by Ocugen Inc, 2021
Diabetic Retinopathy - Pipeline by OcuNexus Therapeutics Inc, 2021
Diabetic Retinopathy - Pipeline by OliPass Corporation, 2021
Diabetic Retinopathy - Pipeline by Opera Therapeutics, 2021
Diabetic Retinopathy - Pipeline by Oxurion NV, 2021
Diabetic Retinopathy - Pipeline by Palatin Technologies Inc, 2021
Diabetic Retinopathy - Pipeline by Phanes Therapeutics Inc, 2021
Diabetic Retinopathy - Pipeline by PharmAbcine Inc, 2021
Diabetic Retinopathy - Pipeline by Pinotbio Inc, 2021
Diabetic Retinopathy - Pipeline by Praetego Inc, 2021
Diabetic Retinopathy - Pipeline by Profarma, 2021
Diabetic Retinopathy - Pipeline by PYC Therapeutics Ltd, 2021
Diabetic Retinopathy - Pipeline by Ranger Biotechnologies AS, 2021
Diabetic Retinopathy - Pipeline by Regeneron Pharmaceuticals Inc, 2021
Diabetic Retinopathy - Pipeline by RegenxBio Inc, 2021
Diabetic Retinopathy - Pipeline by RemeGen Co Ltd, 2021
Diabetic Retinopathy - Pipeline by Retinset SL, 2021
Diabetic Retinopathy - Pipeline by Retrotope Inc, 2021
Diabetic Retinopathy - Pipeline by Reven Pharmaceuticals Inc, 2021
Diabetic Retinopathy - Pipeline by Rezolute Inc, 2021
Diabetic Retinopathy - Pipeline by Ribomic Inc, 2021
Diabetic Retinopathy - Pipeline by Sciwind Biosciences Co Ltd, 2021
Diabetic Retinopathy - Pipeline by Serodus ASA, 2021
Diabetic Retinopathy - Pipeline by SIFI SpA, 2021
Diabetic Retinopathy - Pipeline by Singh Biotechnology LLC, 2021
Diabetic Retinopathy - Pipeline by SiNOPSEE Therapeutics Pte Ltd, 2021
Diabetic Retinopathy - Pipeline by Skye Bioscience Inc, 2021
Diabetic Retinopathy - Pipeline by Skyran Biologics Inc, 2021
Diabetic Retinopathy - Pipeline by SmartinBio, 2021
Diabetic Retinopathy - Pipeline by Stealth BioTherapeutics Corp, 2021
Diabetic Retinopathy - Pipeline by SunBio Inc, 2021
Diabetic Retinopathy - Pipeline by Surrozen Inc, 2021
Diabetic Retinopathy - Pipeline by Sylentis SAU, 2021
Diabetic Retinopathy - Pipeline by Teraclon IDF SL, 2021
Diabetic Retinopathy - Pipeline by Topadur Pharma AG, 2021
Diabetic Retinopathy - Pipeline by Translatum Medicus Inc, 2021
Diabetic Retinopathy - Dormant Projects, 2021
Diabetic Retinopathy - Discontinued Products, 2021

List Of Figures


Number of Products under Development for Diabetic Retinopathy, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Top 10 Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Top 10 Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021

Diabetic Neuropathy (Metabolic Disorder) - Drugs in Development, 2021

Diabetic Neuropathy (Metabolic Disorder) - Drugs in Development, 2021Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Neuropathy - Drugs In Development, 2021, provides an overview of the

USD 2000 View Report

Diabetic Foot Ulcers (Metabolic Disorder) - Drugs in Development, 2021

Diabetic Foot Ulcers (Metabolic Disorder) - Drugs in Development, 2021Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Foot Ulcers - Drugs In Development, 2021, provides an overview

USD 2000 View Report

Global Proliferative Diabetic Retinopathy Therapeutics Market Research Report 2023-2027

In the context of China-US trade war and COVID-19 epidemic, it will have a big influence on this market. Proliferative Diabetic Retinopathy Therapeutics Report by Material, Application, and Geography

USD 3200 View Report

Non-Proliferative Diabetic Retinopathy (NPDR) (Metabolic Disorders) - Drugs in Development, 2021

Non-Proliferative Diabetic Retinopathy (NPDR) (Metabolic Disorders) - Drugs in Development, 2021Non-Proliferative Diabetic Retinopathy (NPDR) (Metabolic Disorders) - Drugs in Development, 2021 provides an overview of the Non-Proliferative Diabetic Retinopathy (NPDR)

USD 2000 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available